Sugi Predict

Sugi Predict / Compounds / SCHEMBL2925943

SCHEMBL2925943

SCHEMBL2925943

CS(=O)(=O)c1ccc2[nH]c(C(=O)O)cc2c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIN1 Q13526 1/20 0.61
▸ SMAD3 P84022 1/20 0.58
▸ KDM4E B2RXH2 3/20 0.57
▸ HPGD P15428 3/20 0.57
▸ HSD17B10 Q99714 3/20 0.57
▸ ALDH1A1 P00352 2/20 0.57
▸ LMNA P02545 2/20 0.57
▸ F7 P08709 1/20 0.57
▸ F3 P13726 1/20 0.57
▸ PDPK1 O15530 1/20 0.57
▸ TSHR P16473 1/20 0.57
▸ NFKB1 P19838 1/20 0.57
▸ APEX1 P27695 1/20 0.57
▸ CYP2C19 P33261 1/20 0.57
▸ TDP1 Q9NUW8 1/20 0.57
▸ SRD5A2 P31213 2/20 0.53
▸ MAPT P10636 1/20 0.53
▸ DAO P14920 1/20 0.53
▸ KMT2A Q03164 1/20 0.50
▸ GPR35 Q9HC97 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30147570 1.00 PIN1 (0.61) PIN1SMAD3KDM4EHPGDHSD17B10
Guanidine SCHEMBL8691290 0.92 PIN1 (0.52) PIN1SMAD3KDM4EHPGDHSD17B10
SCHEMBL12862880 0.87 PIN1 (0.45) PIN1SMAD3KDM4EHPGDHSD17B10
SCHEMBL3641212 0.87 EIF4A3 (0.56) PIN1SMAD3KDM4EHPGDHSD17B10
SCHEMBL3283474 0.86 MMP2 (0.45) PIN1SMAD3KDM4EHPGDHSD17B10
SCHEMBL6521147 0.84 PIN1 (0.58) PIN1SMAD3KDM4EHPGDHSD17B10
SCHEMBL1159366 0.84 SMAD3 (0.58) PIN1SMAD3KDM4EHPGDHSD17B10
SCHEMBL12392281 0.83 PIN1 (0.45) PIN1SMAD3KDM4EHPGDHSD17B10
SCHEMBL30147567 0.83 ALOX15 (0.51) PIN1KDM4ECYP2C9MMP2MMP13
SCHEMBL2576116 0.83 XDH (0.56) PIN1KDM4EHPGDHSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-07-11 — — US disclosed
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-07-11 — — US disclosed
US-20230190939-A1 ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF INTOCELL, INC. (KR) 2023-06-22 — — US disclosed
US-20230190939-A1 ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF INTOCELL, INC. (KR) 2023-06-22 — — US disclosed
WO-2021260438-A1 ANTIBODY-DRUG CONJUGATES COMPRISING ANTI-B7-H3 ANTIBODIES INTOCELL, INC. (KR) 2021-12-30 — — WO disclosed
US-8889878-B2 Haloalky-substituted amides as insecticides and acaricides BAYER CROPSCIENCE AG (DE) 2014-11-18 — — US disclosed
EP-1451185-B1 INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS SANOFI AVENTIS DEUTSCHLAND (DE) 2014-08-06 — — EP disclosed
US-8710242-B2 Haloalky -substituted amides as insecticides and acaricides BAYER CROPSCIENCE AG (DE) 2014-04-29 — — US disclosed
US-20130172390-A1 Haloalkyl-Substituted Amides as Insecticides and Acaricides BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-07-04 — — US disclosed
EP-1086950-B1 HETEROCYCLIC INDOLE DERIVATIVES AND MONO- OR DIAZAINDOLE DERIVATIVES CHUGAI PHARMACEUTICAL CO LTD (JP) 2010-09-29 — — EP disclosed
CN-1433411-A Compound (I) ASTRAZENECA AB (SE) 2003-07-30 — — CN disclosed
WO-2003044014-A1 INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-05-30 — — WO disclosed
EP-1314733-A1 Indole-2-carboxamides as factor Xa inhibitors Aventis Pharma Deutschland GmbH (DE) 2003-05-28 — — EP disclosed
US-6525070-B2 For therapy of chemokine (such as CCR3) or H1 mediated disease state ASTRAZENECA AB (SE) 2003-02-25 — — US disclosed
EP-1274701-A1 CHEMICAL COMPOUNDS AstraZeneca AB (SE) 2003-01-15 — — EP disclosed
US-20020077337-A1 Chemical compounds ASTRAZENECA AB (SE) 2002-06-20 — — US disclosed
US-6337344-B1 ANTICOAGULANTS AND ENZYME INHIBITORS FOR CARDIOVASCULAR DISORDERS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-01-08 — — US disclosed
WO-2001077101-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2001-10-18 — — WO disclosed
EP-1042287-A1 INDOLE DERIVATIVES AS INHIBITORS OF FACTOR XA Aventis Pharma Deutschland GmbH (DE) 2000-10-11 — — EP disclosed
WO-1999033800-A1 INDOLE DERIVATIVES AS INHIBITORS OR FACTOR XA AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 1999-07-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230190939-A1 ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF CD47, ENPP2, CD2 PIN1 1185/4885SMAD3 1226/4885KDM4E 2459/4885
US-20020077337-A1 Chemical compounds CCR3, CCR1, CCR4 PIN1 619/4885SMAD3 257/4885KDM4E 3900/4885
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME SLC10A1, NR1H4, SLC10A2 PIN1 70/4885SMAD3 463/4885KDM4E 1496/4885
US-20130172390-A1 Haloalkyl-Substituted Amides as Insecticides and Acaricides CRYAA, ACLY, CRYZ PIN1 3194/4885SMAD3 4189/4885KDM4E 1789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.